ALLO
Wall Street’s mood ring is flashing green
Allogene Therapeutics is getting a friendly nod from analysts, with consensus now sitting at a “Moderate Buy” after coverage from 15 firms. The average 12-month price target lands at $8.44, which is basically Wall Street saying, “We like the story… just maybe not the share price right this second.”
The not-so-small dilution elephant in the room
Here’s the catch: the stock just raised about $200.4 million in a public offering, and that kind of capital raise can feel a little like finding out your pizza got bigger because they cut the slices into more pieces. Great if you’re starving for cash runway. Less great if you already own the equity.
That offering has weighed on the stock, and the article notes a sharp post-deal drop of roughly 13% in one report. So even as analysts get more constructive, the market is still very much in “show me” mode.
Why you should care
For investors, this is the classic biotech tradeoff:
- Bull case: more cash, more runway, and analysts still seeing upside from here
- Bear case: dilution, insider selling, and a stock that got smacked after the raise
- Translation: the science may be getting attention, but the cap table is doing its best impression of a wet blanket
Big picture: analysts are warming up, but Allogene still has to prove the business can outrun the dilution hangover.